MMD PCR for lung cancer driver mutations

MMD PCR 检测肺癌驱动突变

• 批准号: 131679
• 金额: $ 3.18万
• 依托单位: GENEFIRST LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=131679
• 关键词: MMD; PCR; lung; cancer; driver

Personalised medicine aims to predict in advance which patients are most likely to benefit from, or not respond well to, a particular therapy. However, current methods have significant limitations in terms of both sensitivity and cost. Tumour biopsies, particularly from lung cancers, often provide only a tiny amount of material. Furthermore there may be change in mutations with time, and therefore repeated testing is needed at intervals during treatment, but repeated biopsy is highly undesirable for some tumour types. It has recently been discovered that DNA from tumours leaks into blood and can be detected, if the method is sufficiently sensitive. GeneFirst is developing a new real-time PCR based technology for detection of multiple defined mutations in a single closed-tube with greatly increased sensitivity. This is potentially suitable for detecting mutations using circulating cell-free DNA in blood.

个性化医疗旨在提前预测哪些患者最有可能从特定治疗中受益，或对特定治疗反应不佳。然而，目前的方法在灵敏度和成本方面都有很大的局限性。肿瘤活检，特别是肺癌，通常只能提供少量的材料。此外，随着时间的推移，突变可能会发生变化，因此在治疗期间需要间隔进行重复检测，但对于某些肿瘤类型，重复活检是非常不可取的。最近发现，如果方法足够灵敏，则可以检测到肿瘤的DNA泄漏到血液中。GeneFirst正在开发一种新的基于实时PCR的技术，用于在单个封闭管中检测多个定义的突变，灵敏度大大提高。这可能适用于使用血液中的循环无细胞DNA检测突变。